tradingkey.logo

Pacific Biosciences of California Inc

PACB
1.770USD
-0.110-5.85%
收盤 12/26, 16:00美東報價延遲15分鐘
534.28M總市值
虧損本益比TTM

Pacific Biosciences of California Inc

1.770
-0.110-5.85%

關於 Pacific Biosciences of California Inc 公司

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Pacific Biosciences of California Inc簡介

公司代碼PACB
公司名稱Pacific Biosciences of California Inc
上市日期Oct 27, 2010
CEOHenry (Christian O)
員工數量575
證券類型Ordinary Share
年結日Oct 27
公司地址1305 O'brien Drive
城市MENLO PARK
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94025
電話16505218000
網址https://www.pacb.com/
公司代碼PACB
上市日期Oct 27, 2010
CEOHenry (Christian O)

Pacific Biosciences of California Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
696.81K
-17.96%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
110.00K
-17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
110.00K
-17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Hannah A. Valantine, M.D.
Dr. Hannah A. Valantine, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Smith
Mr. Christopher M. (Chris) Smith
Independent Director
Independent Director
--
--
Dr. Lucy Shapiro, Ph.D.
Dr. Lucy Shapiro, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Mark Van Oene
Mr. Mark Van Oene
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jim R. Gibson
Mr. Jim R. Gibson
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
--
--
Ms. Kathy P. Ordonez
Ms. Kathy P. Ordonez
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
696.81K
-17.96%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
110.00K
-17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
110.00K
-17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Hannah A. Valantine, M.D.
Dr. Hannah A. Valantine, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Smith
Mr. Christopher M. (Chris) Smith
Independent Director
Independent Director
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Consumable revenue
18.93M
47.61%
Instrument revenue
14.15M
35.58%
Service And Other
6.68M
16.81%
地區USD
名稱
營收
佔比
North America
17.69M
44.48%
Asia Pacific
12.61M
31.72%
Europe (including the Middle East and Africa)
9.47M
23.81%
業務
地區
業務USD
名稱
營收
佔比
Consumable revenue
18.93M
47.61%
Instrument revenue
14.15M
35.58%
Service And Other
6.68M
16.81%

股東統計

更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
ARK Investment Management LLC
10.24%
SoftBank Group Corp
6.77%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.43%
Edmond de Rothschild Asset Management (France) S.A.
3.54%
其他
67.44%
持股股東
持股股東
佔比
ARK Investment Management LLC
10.24%
SoftBank Group Corp
6.77%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.43%
Edmond de Rothschild Asset Management (France) S.A.
3.54%
其他
67.44%
股東類型
持股股東
佔比
Investment Advisor
37.57%
Investment Advisor/Hedge Fund
10.88%
Holding Company
6.77%
Hedge Fund
3.17%
Individual Investor
1.16%
Corporation
1.16%
Research Firm
1.13%
Sovereign Wealth Fund
0.40%
Bank and Trust
0.15%
其他
37.61%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
566
166.98M
55.32%
-97.69M
2025Q2
600
214.62M
71.52%
-110.62M
2025Q1
629
227.30M
75.82%
-104.21M
2024Q4
625
258.31M
94.32%
-61.55M
2024Q3
618
231.32M
84.94%
-85.30M
2024Q2
629
240.26M
88.29%
-64.03M
2024Q1
637
265.38M
97.57%
-38.04M
2023Q4
643
276.71M
103.53%
-9.49M
2023Q3
631
258.82M
103.48%
-18.47M
2023Q2
639
248.61M
99.68%
-37.06M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
ARK Investment Management LLC
36.30M
12.08%
-180.28K
-0.49%
Jun 30, 2025
SoftBank Group Corp
20.45M
6.81%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.97M
6.65%
-470.54K
-2.30%
Jun 30, 2025
The Vanguard Group, Inc.
16.02M
5.33%
-197.42K
-1.22%
Jun 30, 2025
Edmond de Rothschild Asset Management (France) S.A.
13.37M
4.45%
-8.49M
-38.84%
Jun 30, 2025
Amova Asset Management Co., Ltd.
9.22M
3.07%
-346.88K
-3.63%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.72M
2.24%
+401.64K
+6.36%
Jun 30, 2025
State Street Investment Management (US)
5.75M
1.92%
-625.01K
-9.80%
Jun 30, 2025
Madrone Advisors, LLC
16.76M
5.58%
-6.63M
-28.34%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
ARK Genomic Revolution ETF
2.3%
iShares Genomics Immunology and Healthcare ETF
1.31%
Invesco NASDAQ Future Gen 200 ETF
0.96%
Global X Genomics & Biotechnology ETF
0.69%
ARK Innovation ETF
0.58%
AXS Green Alpha ETF
0.58%
WisdomTree BioRevolution Fund
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.07%
查看更多
ARK Genomic Revolution ETF
佔比2.3%
iShares Genomics Immunology and Healthcare ETF
佔比1.31%
Invesco NASDAQ Future Gen 200 ETF
佔比0.96%
Global X Genomics & Biotechnology ETF
佔比0.69%
ARK Innovation ETF
佔比0.58%
AXS Green Alpha ETF
佔比0.58%
WisdomTree BioRevolution Fund
佔比0.48%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.09%
ProShares Ultra Nasdaq Biotechnology
佔比0.08%
Invesco Nasdaq Biotechnology ETF
佔比0.07%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Pacific Biosciences of California Inc的前五大股東是誰?

Pacific Biosciences of California Inc的前五大股東如下:
ARK Investment Management LLC
持有股份:36.30M
佔總股份比例:12.08%。
SoftBank Group Corp
持有股份:20.45M
佔總股份比例:6.81%。
BlackRock Institutional Trust Company, N.A.
持有股份:19.97M
佔總股份比例:6.65%。
The Vanguard Group, Inc.
持有股份:16.02M
佔總股份比例:5.33%。
Edmond de Rothschild Asset Management (France) S.A.
持有股份:13.37M
佔總股份比例:4.45%。

Pacific Biosciences of California Inc的前三大股東類型是什麼?

Pacific Biosciences of California Inc 的前三大股東類型分別是:
ARK Investment Management LLC
SoftBank Group Corp
BlackRock Institutional Trust Company, N.A.

有多少機構持有Pacific Biosciences of California Inc(PACB)的股份?

截至2025Q3,共有566家機構持有Pacific Biosciences of California Inc的股份,合計持有的股份價值約為166.98M,占公司總股份的55.32% 。與2025Q2相比,機構持股有所增加,增幅為-16.20%。

哪個業務部門對Pacific Biosciences of California Inc的收入貢獻最大?

在FY2025Q2,Consumable revenue業務部門對Pacific Biosciences of California Inc的收入貢獻最大,創收18.93M,占總收入的47.61% 。
KeyAI